Iterum Therapeutics Plc (NASDAQ: ITRM) reported Q1 EPS of ($0.38), $0.33 better than the analyst estimate of ($0.71).
Outlook:
Based on Iterum’s current operating plan, Iterum expects that its current cash, cash equivalents and short-term investments will be sufficient to fund its operations into 2025, including through the expected Prescription Drug User Fee Act (PDUFA) date early in the fourth quarter of 2024.

For earnings history and earnings-related data on Iterum Therapeutics Plc (ITRM) click here.